Optomed, the Finnish medical device manufacturer, has launched a hand-held fundus camera alongside its software solution for diabetic retinopathy screening.
The Optomed Aurora camera and Optomed Avenue software solution have been designed to lower the cost of diabetic retinopathy screenings so that fundus screenings can be provided to a wider patient base.
Chief executive officer at Optomed, Seppo Kopsala, said: “These new products are the biggest and most significant development investment in Optomed’s history.”
“We are committed to providing our customers across the world with the most cost-effective solutions for screening, diagnosing and monitoring of blinding eye diseases,” he added.
Optomed Aurora has a 50-degrees field of view, featuring a four-inch colour screen with simple menus and icons. It will be available in selected European markets from 2018.
The software solution, Optomed Avenue, analyses retinal images automatically and provides results in seconds if the patient has an elevated risk of diabetic retinopathy. It is available now in Europe.